Prograf-XL + Prograf + MMF
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Transplantation
Conditions
Kidney Transplantation, Transplantation Immunology, Host vs Graft Reaction
Trial Timeline
Dec 1, 2007 → Apr 1, 2010
NCT ID
NCT00717678About Prograf-XL + Prograf + MMF
Prograf-XL + Prograf + MMF is a phase 3 stage product being developed by Astellas Pharma for Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00717678. Target conditions include Kidney Transplantation, Transplantation Immunology, Host vs Graft Reaction.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Transplantation were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00717678 | Phase 3 | Completed |
| NCT00720408 | Phase 3 | Completed |
Competing Products
20 competing products in Kidney Transplantation